Geode Capital Management
CGEM icon

Geode Capital Management’s Cullinan Oncology CGEM Stock Holding History

Geode Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.2M Buy
1,547,309
+179,041
+13% +$2.66M ﹤0.01% 1960
2026
Q1 		$19.4M Buy
1,368,268
+66,006
+5% +$848K ﹤0.01% 2007
2025
Q4 		$13.5M Buy
1,302,262
+6,942
+0.5% +$62.6K ﹤0.01% 2240
2025
Q3 		$7.68M Buy
1,295,320
+15,824
+1% +$116K ﹤0.01% 2566
2025
Q2 		$9.64M Buy
1,279,496
+37,679
+3% +$303K ﹤0.01% 2392
2025
Q1 		$9.4M Buy
1,241,817
+27,176
+2% +$261K ﹤0.01% 2330
2024
Q4 		$14.8M Buy
1,214,641
+6,220
+0.5% +$89.4K ﹤0.01% 2125
2024
Q3 		$20.2M Buy
1,208,421
+231,935
+24% +$4.11M ﹤0.01% 1969
2024
Q2 		$17M Buy
976,486
+299,156
+44% +$6.37M ﹤0.01% 2025
2024
Q1 		$11.5M Buy
677,330
+21,666
+3% +$335K ﹤0.01% 2243
2023
Q4 		$6.68M Buy
655,664
+64,841
+11% +$574K ﹤0.01% 2555
2023
Q3 		$5.35M Buy
590,823
+78,477
+15% +$817K ﹤0.01% 2601
2023
Q2 		$5.51M Sell
512,346
-25,477
-5% -$271K ﹤0.01% 2627
2023
Q1 		$5.5M Sell
537,823
-19,285
-3% -$213K ﹤0.01% 2596
2022
Q4 		$5.88M Buy
557,108
+15,588
+3% +$189K ﹤0.01% 2582
2022
Q3 		$6.94M Buy
541,520
+36,526
+7% +$492K ﹤0.01% 2484
2022
Q2 		$6.47M Buy
504,994
+62,453
+14% +$708K ﹤0.01% 2553
2022
Q1 		$4.63M Buy
442,541
+10,670
+2% +$144K ﹤0.01% 2837
2021
Q4 		$6.66M Buy
431,871
+10,633
+3% +$212K ﹤0.01% 2722
2021
Q3 		$9.51M Buy
421,238
+188,316
+81% +$5.04M ﹤0.01% 2479
2021
Q2 		$6M Buy
232,922
+12,655
+6% +$389K ﹤0.01% 2794
2021
Q1 		$9.18M Buy
+220,267
New +$8.94M ﹤0.01% 2417

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Geode Capital Management's CGEM Position: Q2 2026 in Review

Geode Capital Management increased its Cullinan Oncology (CGEM) stake by 13% in Q2 2026, buying an estimated $2.66M and bringing the position to 1,547,309 shares worth $28.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1960.

Geode Capital Management first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Geode Capital Management held 1,547,309 shares of Cullinan Oncology worth $28.2M as of Q2 2026.
  • Geode Capital Management bought 179,041 Cullinan Oncology shares in Q2 2026, an estimated $2.66M.
  • Cullinan Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1960 holding.
  • Geode Capital Management first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.